Progesterone in Gender Affirming Hormone Therapy Study

Launched by EMORY UNIVERSITY · Jan 29, 2025

Keywords

ClinConnect Summary

The "Progesterone in Gender Affirming Hormone Therapy Study" is a clinical trial that is looking at how oral progesterone affects transgender women who are already receiving hormone therapy. The main goal is to see if progesterone can help reduce feelings of psychological distress. The study will also explore its impact on sleep quality, breast size, overall quality of life, feelings of alignment with gender identity, and heart health.

To participate in this study, you need to be a transgender woman who has been on hormone therapy for at least six months. However, there are some health conditions that may prevent you from joining, such as liver disease, certain heart problems, or a history of breast cancer. If you decide to take part, you can expect to be monitored for various health effects throughout the study. This research aims to better understand the role of progesterone in supporting the well-being of transgender women.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • - Participants will be transgender women, who have been on gender-affirming hormone therapy for at least 6 months before the start of the study.
• Exclusion Criteria:
• • Peanut allergy
• • Liver disease (liver enzyme elevations and/or evidence of acute or chronic hepatitis). In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
• • Stage 4/5 chronic kidney disease
• • Congestive heart failure
• • Medical disease or medication use associated with gynecomastia (i.e tumor, hyperthyroidism, chronic kidney disease, cirrhosis, ACE inhibitors, statins, haloperidol, tricyclic antidepressants, atypical antipsychotics)
• • Pre-existing cardiovascular disease
• • Prior or current history of thromboembolism, known clotting disorders, current or recent anti-thrombotic therapy for venous thromboembolism.
• • History of breast cancer
• • Prior progesterone use
• • Uncontrolled depression and/or suicidal ideation
• • Current hypothyroidism (even if controlled with treatment) Progesterone in Gender Affirming Hormone Therapy 9 Version #4, 10/30/24
• • Current or recent (in the past 6 months) cannabis use
• • Previously identified BRCA 1 or 2 gene mutation or other familial breast cancer.
• • Abnormal mammogram (if indicated - for patients above the age of 50 and on estrogen for 5 or more years OR positive family history of breast cancer) with results of BIRADS 3 or higher. Subjects with a BIRADS 0 mammogram must have undergone additional imaging demonstrating BIRADS 1 or 2 prior to enrollment.
• • Have had or are planning to undergo breast enhancement or gender affirming top surgery in the next 6 months
• • Uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mmHg.
• • Triglycerides ≥ 500 mg/dL.
• • In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
• • Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2.
• • Estradiol levels outside the stable range (100-200 pg/mL)
• • Heavy smoking, defined as 25+ cigarettes per day
• • Non-English speaking or those with limited English proficiency